Related by context. All words. (Click for frequent words.) 73 HER2/neu 71 Mesothelin 71 EpCAM 71 CanAg 70 acid phosphatase PAP 70 carcinoembryonic antigen CEA 70 AGTR1 69 GPNMB 69 MAGE A3 protein 68 Epidermal Growth Factor Receptor 68 PKCi 68 somatostatin receptors 68 LHRH receptors 68 HER2 receptor 68 NY ESO 68 epithelial tumors 68 MAGE A3 ASCI 67 NSCLC tumors 67 Her2/neu 67 carcinoembryonic antigen 67 HER-2/neu 67 P selectin 67 SNT-MC#/idebenone 67 folate receptor 67 tumor specific antigen 67 metastatic colorectal 67 mesothelin 67 Aflibercept 67 MLL AF9 67 TTR gene 67 WT1 67 TRAIL R2 67 prostate cancer antigen prostatic 67 MGd 67 PC# cells 67 HER2 expression 67 MORAb 66 peripheral blood mononuclear 66 colorectal gastric 66 BRAF V#E mutation 66 FLT3 66 HER2 ErbB2 66 interleukin IL -# 66 K ras mutations 66 antibody MAb 66 neuroblastoma tumors 66 EGFRvIII 66 breast carcinomas 66 multiple myeloma MM 66 syngeneic 66 Virulizin ® 66 VSV G 65 Gleevec resistant 65 tumorigenicity 65 HER2/neu gene 65 colorectal carcinoma 65 cytokeratin 65 hypereosinophilic syndrome 65 breast pancreatic 65 gastrointestinal stromal tumors GIST 65 pan HDAC inhibitor 65 IGF IR 65 BRAF mutation 65 humanised monoclonal antibody 65 Preclinical Study 65 colorectal carcinomas 65 Vitaxin 65 EGFr 65 huC# DM4 65 HER2 overexpression 65 HER2 neu 65 liposomal doxorubicin 65 cMET 65 MUC1 65 HepG2 cells 65 recurrent glioblastoma multiforme 65 serum antibody 65 chimeric monoclonal antibody 65 metastatic melanomas 65 PSMA ADC 65 Endometrial 65 androgen receptor AR 65 Epratuzumab 65 HQK 65 EGF receptor 65 VEGFR1 65 gastrointestinal stromal tumors GISTs 65 humanised antibody 65 SPINK1 65 colon carcinoma 65 CD# CD# 64 anaplastic lymphoma kinase ALK 64 CD# + [001] 64 Factor Receptor 64 HGS ETR2 64 Cervista HPV HR 64 hA# 64 T#I [002] 64 hCG beta 64 Recombinant Human 64 Enzastaurin 64 YONDELIS 64 fosbretabulin 64 ovarian carcinoma 64 HAAH 64 Antitumor Activity 64 KRAS mutations 64 tumor antigen 64 III EGFRvIII 64 tumors GIST 64 vimentin 64 completely resected 64 Monoclonal antibody 64 myelodysplastic myeloproliferative diseases 64 BRAF V#E 64 Gefitinib 64 targeting CD# 64 FUS1 64 retinoic acid receptor 64 cisplatin resistant 64 Immunohistochemical analysis 64 p#HER# 64 M2 subunit 64 CEACAM1 64 humanized antibody 64 metastatic neuroendocrine tumors 64 Olaparib 64 pancreatic carcinoma 64 castrate resistant 64 Kahalalide F 64 CD# antigen 64 Clusterin 64 histone deacetylase inhibitor 64 antiproliferative effects 64 Cell Lymphoma 64 #T# tumor 64 Kinoid 64 chemokine receptor 64 K ras 64 specific lectin receptors 64 ALDH 64 #I TM# 64 mertansine 64 bladder ovarian 64 hemagglutination inhibition 64 HGS ETR1 64 mapatumumab 63 PC3 cells 63 Vidaza azacitidine 63 MVA BN ® 63 compound AEZS 63 A3 adenosine receptor 63 trastuzumab Herceptin ® 63 antibody titer 63 mutated KRAS gene 63 MVA MUC1 IL2 63 HCV replicon 63 bronchial epithelial cells 63 gemcitabine carboplatin 63 stage IIIb IV 63 V#F 63 Ki# 63 p# biomarker 63 HER2/neu protein 63 effector function 63 GW# [003] 63 IL#B 63 Multimeric 63 Squamous 63 EGFR receptor 63 Antigen Specific 63 pDCs 63 mutated K ras 63 OMP #M# 63 leukemia AML 63 monocytes macrophages 63 GRNCM1 63 HIF 1alpha 63 immunohistochemical 63 Initiate Clinical Trial 63 recurrent glioma 63 PBMCs 63 mutated KRAS 63 interferon γ 63 BRAF mutations 63 IMA# 63 TNFa 63 TMPRSS2 ERG 63 sunitinib Sutent 63 hENT1 63 Pertuzumab 63 estrogen receptor ER 63 depsipeptide 63 malignant ascites 63 recurrent NSCLC 63 hCG β 63 annexin 63 CYT# potent vascular disrupting 63 Neuvenge 63 Cytochrome P# 63 E#F# 63 OncoVEX GM CSF 63 efaproxiral 63 RAV# 63 prostate epithelial cells 63 Modified Vaccinia Ankara 63 enkephalin 63 liver metastases 63 Ceflatonin 63 histologies 63 humanized monoclonal antibodies 63 Cethromycin 63 hepatoma 63 GRNVAC1 63 binds selectively 63 flavopiridol 63 SIR Spheres 63 E selectin 63 nonsmall cell lung cancer 63 pancreatic adenocarcinoma 63 mTOR mammalian target 63 LHRH receptor positive 63 PDGF receptor 63 c MYC 63 protein tyrosine phosphatase 1B 63 peptide antigens 63 riociguat 63 EGFR mutation 63 Cytotoxic T 63 TGF alpha 63 masitinib 63 activin 63 plasma pharmacokinetics 63 EGFR protein 63 gastric adenocarcinoma 63 miR #a [001] 63 Hsp# Inhibitor 63 immunohistochemical staining 63 intratumoral injection 63 XL# inhibits 63 HER1 63 CCR9 63 chronic eosinophilic leukemia 63 renal cell carcinomas 63 Peginterferon alfa 2b 63 Novel Small Molecule 63 IGFBP 3 63 eIF 4E 63 ALN TTR 63 CD# molecule 62 Afatinib 62 SOD1 gene 62 GSTP1 62 DLL4 62 low expressors 62 olaparib 62 IgG1 antibody 62 EGFR mutations 62 demonstrated antitumor activity 62 DEB# 62 milatuzumab 62 hTERT 62 azacytidine 62 Janus kinase 62 metastatic malignant 62 Immunohistochemical 62 ChR2 62 biodistribution 62 relapsed MM 62 CCR5 mAb 62 CTAP# Capsules 62 CEQ# 62 Immunotherapeutic 62 Antitumor 62 whose tumors overexpress 62 nonmetastatic 62 epithelial cells lining 62 Campath alemtuzumab 62 inhibitory receptor 62 glioma cells 62 RRM1 62 SCIg 62 Cutaneous T 62 Xelox 62 PARP inhibitor 62 Azedra 62 Ocrelizumab 62 selective modulator 62 adjuvant cisplatin 62 Exherin TM 62 Decitabine 62 MUC1 protein 62 PEGylated Fab fragment 62 Interferon Beta 62 neovasculature 62 ZFN modified 62 RhuDex R 62 CD#c 62 idiotype protein 62 viral kinetics 62 Irinotecan 62 TOP2A 62 ErbB2 positive 62 stage IIIB 62 OncoVex 62 Romidepsin 62 tNOX 62 Tie2 62 Granulocyte Colony Stimulating Factor 62 GRN# 62 CLL SLL 62 Zolinza 62 generation antisense inhibitor 62 p#INK#a 62 Trastuzumab Herceptin 62 MET amplification 62 prostate carcinoma 62 pain palliation 62 immunoglobulin G 62 galectins 62 IL #R 62 preclinical efficacy 62 LHRH receptor 62 EGFR mutant 62 Leukemias 62 HCV SPRINT 62 metastatic gastric 62 Anticalins ® 62 glioblastoma tumors 62 telomerase reverse transcriptase 62 histone deacetylase HDAC inhibitor 62 S#A# [002] 62 cell lymphoma CTCL 62 HuMax EGFr 62 INCB# [003] 62 PEG IFN 62 EphA2 62 Azacitidine 62 paclitaxel cisplatin 62 Inactivation 62 thymidylate synthase TS 62 Estrogen Receptor 62 bFGF 62 mda 7 62 adenoviral 62 cytochrome P 62 TRO# 62 MAb 62 transfected cells 62 subependymal giant cell 62 Endothelial Cells 62 FGFR1 62 Metastatic Melanoma 62 JVRS 62 ERalpha 62 Mucosal 62 STRIDE PD 62 multicenter Phase II 62 trastuzumab Herceptin R 62 PCA3 gene 62 Phase 2b Clinical Trial 62 ZACTIMA 62 DermaVir 62 VitiGam 62 MenACWY 62 Prolongs Survival 62 Golimumab 62 vinca alkaloid 62 HGPIN 62 miR #b [001] 62 cediranib 62 Her2 62 vWF 62 5alpha reductase 62 TroVax ® 62 Leydig cell 62 huN# DM1 62 selectively inhibited 62 lymphocytosis 62 bispecific antibody 62 lymphoid malignancies 62 castrate resistant prostate cancer 62 HEK# cells 62 INGN 62 Aplidin 62 miRview ™ squamous 62 oral prodrug 62 pulmonary metastases 61 Liposomal 61 KRAS mutation 61 ALB # 61 advanced metastatic renal 61 IFN γ 61 metastatic colorectal carcinoma 61 PD LID 61 Aplidin R 61 IgG antibodies 61 IFN α 61 HIF 1a 61 RECIST Response Evaluation Criteria 61 radezolid 61 nucleolin 61 IGFBP2 61 gefitinib Iressa 61 refractory chronic myeloid 61 radiolabeled 61 dose escalation clinical 61 HBsAg 61 histological subtype 61 Muraglitazar 61 tarenflurbil 61 Her-2/neu 61 pediatric acute lymphoblastic 61 metastatic pancreatic 61 vitro cytotoxicity 61 metaglidasen 61 Sipuleucel T 61 radioimmunotherapy RIT 61 ACTEMRA TM 61 prostate cancer mCRPC 61 anti CD3 antibody 61 refractory chronic lymphocytic 61 DCVax 61 GBM tumors 61 immunohistochemical analysis 61 TRAIL induced apoptosis 61 mRCC 61 HLA DQ2 61 oral JAK1 61 PEG SN# 61 ELISPOT 61 miRview mets 61 adecatumumab 61 haematologic malignancies 61 Chronic Lymphocytic Leukemia 61 monocytic 61 Sym# 61 iniparib 61 HERCEPTIN 61 CCX# 61 refractory cutaneous T 61 EGFR HER 61 Antigen CEA 61 monoclonal antibody IgG1 Mab 61 extracellular domain 61 KRAS mutant 61 targeted radiotherapeutic 61 bactericidal activity 61 alvespimycin 61 urothelial carcinoma 61 Combination REOLYSIN R 61 N cadherin 61 ribonucleotide reductase clinically validated 61 transgenic rats 61 underwent surgical resection 61 Cell Lung Cancer 61 CXCR4 expression 61 Bezielle 61 SAR# [004] 61 dasatinib Sprycel 61 pegylated liposomal doxorubicin 61 chemoresistant 61 neratinib 61 ERK1 2 61 thymalfasin 61 heparanase 61 pharmacodynamic effects 61 ERCC1 61 HER2 antibody 61 Degarelix 61 cancer immunotherapeutics 61 immunostaining 61 APTIMA HPV 61 nucleotide analog 61 MKC# MT 61 endoglin 61 resected pancreatic cancer 61 AAV2 61 Traficet EN 61 pT2 61 Aliskiren 61 Renal Cell Carcinoma 61 myeloperoxidase 61 sorafenib tablets 61 HER2 gene 61 KRAS oncogene 61 cell adhesion molecule 61 TIMP 61 EGFR activating mutations 61 stably transfected 61 EGFR HER2 61 alveolar epithelial cells 61 Adjuvant Treatment 61 glutamic acid decarboxylase 61 carcinoid 61 HER2 positive cancers 61 novel VDA molecule 61 systemic RNAi therapeutic 61 Nexavar sorafenib 61 Oral Fingolimod 61 synovial tissue 61 humanized monoclonal 61 Pharmacokinetics PK 61 #F FDG 61 proteasome inhibitor 61 Septin9 61 HER2 amplification 61 circulating endothelial cells 61 AAG geldanamycin analog 61 endocrine therapies 61 pancreatic islet 61 tubulin inhibitor 61 #F FDG PET 61 receptor tyrosine kinase inhibitor 61 Papillary 61 aT cell 61 Zarnestra 61 anti EGFR antibody 61 luteinizing hormone releasing 61 peritoneal carcinomatosis 61 metastatic RCC 61 NKX#.# 61 unresectable tumors 61 Cell Lymphoma CTCL 61 hemagglutination inhibition HAI 61 CIMZIA TM 61 dose cohort 61 hCG Beta 61 VitiGam TM 61 Dapagliflozin 61 PPARgamma 61 antitumor effect 61 TIMP 1 61 mCRC patients 61 ENMD # 61 untreated metastatic melanoma 61 Proxinium TM 61 Allogeneic 61 inducible nitric oxide synthase 61 micafungin 61 Tumor Necrosis Factor 61 p# deficient 61 EGFR TKI 61 BMP2 61 Diamyd ® 61 VEGF receptor 61 Tarceva TM 61 CD# CEA 61 Daclizumab 61 PEGylated anti 61 neuroendocrine cancers 61 erlotinib Tarceva ® 61 Clinical Trial Results 61 fluoropyrimidine 61 galiximab 61 Eg5 61 DAVANAT 61 gastrointestinal stromal tumor GIST 61 Patients Treated With 61 recombinant adeno associated 61 Relapsed Refractory 61 refractory metastatic 61 Naive Patients 61 HER2 positive metastatic breast 61 thymidine kinase 61 targeted antifolate 61 neoplastic 61 AT1R 61 grade cervical intraepithelial 61 poly ADP ribose polymerase 61 miRs 61 Wwox 61 dose proportionality 61 lung pancreatic 61 tryptase 61 tyrosine kinase receptor 61 BCR ABL protein 61 lung carcinomas 61 BRAF inhibitor 61 ZOLINZA 61 Onalta 61 p# MAP kinase inhibitor 61 Romiplostim 61 breast carcinoma 61 trastuzumab emtansine T DM1 61 paricalcitol 61 Parathyroid Hormone 60 RhuDex ® 60 CIMZIA ™ 60 INSPIRE Trial Phase III 60 antiviral efficacy 60 CD# [002] 60 epithelial cancers 60 omacetaxine mepesuccinate 60 DNA intercalator 60 Epidermal growth 60 cutaneous T 60 lung adenocarcinomas 60 polyclonal 60 Solid Tumors 60 gastric carcinoma 60 taxane resistant 60 Aurora Kinase 60 Luteinizing Hormone Releasing Hormone 60 EphB4 60 Upregulation 60 receptor blocker 60 Akt activation 60 IgG1 monoclonal antibody 60 inhibits VEGF 60 intercellular adhesion molecule 60 Chronic Lymphocytic Leukemia CLL 60 TLE3 60 Genotypes 60 Bosutinib 60 Hedgehog inhibitor 60 hyperphenylalaninemia HPA due 60 Preclinical Models 60 invasive lobular carcinoma 60 follicular Non Hodgkin 60 Dasatinib 60 davunetide intranasal AL 60 HER2 protein 60 pathophysiological effects 60 pancreatic lung 60 hematological parameters 60 pharmacokinetic PK study 60 monoclonal anti 60 Amrubicin 60 TLK# 60 vidofludimus 60 murine model 60 gastrointestinal stromal tumors 60 humoral responses 60 LymphoStat B belimumab 60 Vandetanib 60 Immunohistochemistry IHC 60 immunoblotting 60 busulfan 60 IGF 1R 60 ABCB1 60 imatinib Gleevec ® 60 CTNNB1 60 colorectal adenocarcinoma 60 pDC 60 IFN gamma 60 mutated BRAF gene 60 iNOS 60 Randomized Phase II 60 BAY #-# 60 Transgenic mice 60 DermaVir Patch 60 Immunohistochemical staining 60 miR #a [002] 60 Castration Resistant Prostate Cancer 60 R roscovitine 60 HNSCC 60 Telbivudine 60 HIF 1α 60 Thiovir 60 carcinoma HCC 60 liposomal amphotericin B 60 INCB# [001] 60 evaluating tivozanib 60 KIF6 gene 60 autologous cellular immunotherapy 60 Hepatocytes 60 anti CD3 60 HBeAg 60 Doxil ® 60 L1 CAM 60 HER2 60 HuLuc# 60 MCSP respectively 60 Tarvacin TM 60 Kinase Inhibitor 60 Insegia 60 FSH receptor 60 hPAM4 60 DCVax R 60 HPV-#/# 60 Antiangiogenic 60 localized renal 60 sorafenib Nexavar 60 Transgenic Mice 60 prostate cancer CaP 60 pancreatic islet cell 60 monoclonal antibody conjugated 60 bronchoalveolar lavage fluid 60 papillary renal cell carcinoma 60 FDG-PET/CT 60 Thrombin 60 Trofex 60 HDACi 60 GISTs 60 carcinoid tumors 60 NS#/#A protease 60 recurrent GBM 60 MEK inhibitor 60 tumor xenograft models 60 cytotoxic T lymphocyte 60 B7 H4 60 antibody MT# 60 Imprime PGG 60 forodesine 60 basal cell carcinoma BCC 60 Pivotal Phase III 60 oncogenic HPV types 60 CA9 SCAN 60 ALK inhibitors 60 ORENCIA ® 60 MF# adjuvanted 60 sodium glucose cotransporter 60 MALT lymphoma 60 orally administered inhibitor 60 investigational humanized monoclonal antibody 60 Omacetaxine 60 soluble tumor necrosis 60 VIR# 60 oral FTY# 60 EGFR expression 60 XmAb# 60 Tyrosine Kinase Inhibitor 60 monoclonal 60 metastatic renal cell carcinoma 60 Stat5 60 alkylating agent 60 CALGB 60 surface glycoprotein 60 ritonavir boosted 60 genitourinary cancers 60 TNFalpha 60 immunological responses 60 lexidronam injection 60 kidney urologic 60 micrometastasis 60 malignant prostate 60 IgM isotype 60 IgG1 antibodies 60 CCR2 60 cells overexpressing 60 accumulate preferentially 60 biliary tract cancer 60 Progenitor Cells 60 skeletal metastases 60 Li Fraumeni 60 B7 H3 60 idiopathic membranous nephropathy 60 Onalta ™ 60 PRTX 60 Solid Tumors criteria 60 tumor xenografts 60 telomerase therapeutic 60 medullary thyroid cancer 60 murine models 60 EGFR tyrosine kinase inhibitors 60 chronic myeloid 60 non nucleoside inhibitor 60 Monoclonal Antibody 60 lymphoid cells 60 NAbs 60 RANTES 60 LHRH 60 BrachySil TM 60 BCIRG 60 immunoreactivity 60 antibody titers 60 satraplatin Phase 60 PhG alpha 1 60 Galectin 3 60 pertuzumab 60 Antiviral Therapy 60 cytologically confirmed 60 recurrent metastatic 60 Safinamide 60 progesterone receptor 60 Trp p8 60 antiangiogenic activity 60 NQO1 60 Vidofludimus 60 hyaluronidase enzyme 60 Initiate Phase 60 HyperAcute 60 activated lymphocytes 60 neoplastic cells 60 neutralizing antibody 60 ependymomas 60 ovarian endometrial 60 elacytarabine 60 HLA DR4 60 LNCaP cells 60 radiation sensitizer 60 caveolin 1 60 Arranon 60 castration resistant 60 Flt3 60 nucleoside analog 60 motesanib 60 non mutated KRAS 60 K RAS 60 alpha#beta# integrin 60 BRCA deficient 60 refractory colorectal cancer 60 JAK2 V#F 60 lymph node metastases 60 IgG4 60 IL #E 60 gene amplification 60 annexin V 60 Lymphocytic 60 lymphoproliferative disorders 60 cytotoxin 60 interferon gamma 1b 60 Alequel 60 adenocarcinomas 60 hepatocellular carcinoma HCC 60 Intravenous CP 60 potent antiproliferative 60 specific CD8 + 60 transmembrane protein 60 HIV HCV coinfected 60 OGG1 60 pancreatic ovarian 60 trabectedin 60 Bavituximab 60 Aurora kinase 60 brivaracetam 60 JAK inhibitors 60 Kit CD# positive 60 Hormone Refractory Prostate Cancer 60 methylation markers 60 splenectomized patients 60 Aptivus ® 60 GATA3 60 antiangiogenic therapy 60 inhibit metastasis 60 Denufosol 60 Successfully Completes Phase 60 VEGF inhibitors 60 florbetaben 60 co stimulatory molecules 60 GPR# [001] 60 Sapacitabine 60 anthracycline chemotherapy 60 Ixempra 60 canakinumab 60 pancreatic prostate 60 CYP#A# CYP#D# 60 TREANDA 60 CHO cells 59 Axitinib 59 underwent resection 59 IL 1ß 59 pCR 59 somatostatin 59 OvaRex MAb 59 Alfacell proprietary ribonuclease 59 replicon 59 PEGylated interferon beta 1a 59 Cardiotoxicity 59 Trandolapril 59 radiotherapeutic 59 miRview TM mets 59 follicular lymphomas 59 standard chemotherapy regimen 59 unresectable stage 59 trastuzumab Herceptin 59 lumiliximab 59 docetaxel Taxotere ® 59 HuMax CD4 59 LRAT 59 somatostatin receptor 59 alemtuzumab Campath 59 interferon IFN 59 viral antigens 59 gastric carcinomas 59 thyroglobulin 59 hypoxia inducible factor 59 SSc 59 IL# PE#QQR 59 TRAIL receptor 59 antisense inhibition 59 IgG1 59 targets Galectin receptors 59 Glufosfamide 59 Anti Tumor Activity 59 GRASPA ® 59 lymphocyte counts 59 HCV protease 59 CIN2 + 59 imatinib resistant 59 genotype 1a 59 S/GSK# 59 p# antigen 59 Hepatocellular Carcinoma HCC 59 histologic subtype 59 BRAF mutant 59 AVASTIN 59 TRAIL Receptor 59 agonistic human 59 HER2 negative 59 cervical lymph node 59 TACI Ig 59 decitabine 59 gp# protein [002] 59 anti PlGF 59 hepatocellular carcinomas 59 prognostic markers 59 Archexin 59 complete cytogenetic response 59 metastatic bladder 59 operable breast cancer 59 Antigens 59 CD# upregulation 59 Advanced Renal Cell 59 comparator arm 59 BZL# 59 phase IIb trial 59 topoisomerase II inhibitor 59 TransVax TM 59 immunohistochemistry IHC 59 Factor VIIa 59 lymphoma subtypes 59 ToGA 59 CD#L 59 CIMZIA TM certolizumab pegol 59 HER3 59 Anti Tumor 59 NPC 1C 59 TRAIL R1 59 MAGE A3 antigen 59 AVADO 59 murine monoclonal antibody 59 pancreatic neuroendocrine tumors 59 5 HT2A serotonin 59 Randomized Study 59 leukaemias 59 AdVac ® 59 beta estradiol 59 immunomodulatory properties 59 Ozarelix 59 cyclin dependent kinase inhibitor 59 Lyn kinase 59 humoral immune response 59 plasmid encoding 59 Gliadel Wafer 59 TRAIL receptors 59 ALN HPN 59 JAK Inhibitor 59 Apoptone 59 imatinib Gleevec 59 CDK4 59 TNF α 59 cancer mCRC 59 PENNVAX ™ B 59 mediated inhibition 59 Renal Cell Carcinoma RCC 59 lutetium plus 59 PI3K inhibitor 59 inhibitor RG# 59 volociximab 59 Randomized Phase 59 circulating EPCs 59 CDKN2A 59 Prednisone Against Refractory 59 humanized interleukin 6 59 colorectal pancreatic 59 Onrigin 59 HGS ETR1 mapatumumab 59 adenoviral vectors 59 rhFVIIa 59 TBC# 59 familial amyloidotic polyneuropathy FAP 59 CCL# 59 recombinant FVIII 59 angiogenesis inhibitor 59 eosinophilic asthma 59 bleomycin 59 Polymorphisms 59 hedgehog pathway 59 Onconase 59 squamous cell lung cancer 59 myelofibrosis polycythemia vera 59 UPLYSO 59 serum antibodies 59 cellular immunotherapy 59 taxane refractory 59 Sutent sunitinib 59 NOD SCID mice 59 GLYX 59 novel therapeutic antibodies 59 biologic therapeutics 59 Boceprevir 59 Mutational 59 baseline LDH 59 FGFR 59 #T# L1 59 selective agonist 59 Lymph node